Wenda Pharmaceutical BET inhibitors were approved clinically.

According to the latest data on the website of the Drug Review Center (CDE) of the State Drug Administration of China, NHWD-870 HCl tablets, a class 1 innovative drug jointly declared by Wenda Pharmaceuticals and Hengya Pharmaceuticals, have obtained two clinical tacit licenses in China to develop treatments for advanced recurrence of non-Hodgkin's lymphoma, skin/mucosal melanoma, non-small cell lung cancer and small cell lung cancer.
NHWD-870 is a new, powerful BET inhibitor to be developed for the treatment of multiple solid tumors.
this is the first innovative anti-tumor drug that Wenda Pharmaceuticals has entered clinical development.
: CDE Screenshot Now, BET family protein has become one of the new targets for scientists to develop innovative cancer therapies.
and end-of-end (BET) protein families consist of four proteins: BRD2, BRD3, BRD4 and BRDT.
, BET eggs are widely expressed in human tissue and are involved in the regulation of gene transcription.
, brominated domain protein 4 (BRD4) is the most important functional protein in the BET family, which regulates DNA replication and gene expression through histoprotein acetylation, thus affecting the cell cycle process.
recent years, it has been found that the abnormal function of bet family is also closely related to the occurrence, immersion, metastasis and other processes of tumors.
as a powerful, new BRD4 inhibitor, NHWD-870 can induce tumor apoptosis by targeting the BRD4 domain, thus achieving anti-tumor effect.
according to public information, the drug was originally developed by a team of Professor Chen Xiang and Professor In Mingzhu of Xiangya Hospital, Central South University, and is currently being developed by Wenda Pharmaceuticals and Hengya Pharmaceuticals.
NHWD-870 showed strong anti-tumor activity in nine different mouse tumor models, according to a study published in the April 2020 issue of the journal Nature Communications.
NHWD-870 inhibited activity was 5-50 times higher than that of similar compounds.
results of pharmacodynamics also showed that NHWD-870 had better oral absorption, metabolism and bio-utilization, and oral NHWD-870 showed good tumor penetration.
in cancer, tumor-related macrophages (TAM) promote tumor growth and cancer metastasis by secreting growth factors and chemical attractors.
researchers found that in addition to being able to lower c-MYC and directly inhibit tumor cell proliferation, NHWD-870 can also block the proliferation of tumor-related macrophages through a variety of mechanisms, some of which are used to stimulate the expression and secretion of CSF1 by reducing tumor cell macrophage colonization.
specifically, BRD4 induces CSF1 expression through a low oxygen induction factor (HIF1 alpha), while NHWD-870 is seen to inhibit CSF1 by inhibiting BRD4 and its target HIF1 alpha.
Photo Source: Resources: In the first half of 2020, Wenda Pharmaceuticals and Hengya Pharmaceuticals jointly submitted a clinical trial application for NHWD-870 to the Drug Review Center (CDE) of the State Drug Administration of China, which was accepted by CDE on June 3.
Reference Center of the State Drug Administration of China. Retrieved Aug 11,2020, from .2 Yin, M., Guo, Y., et al. (2020). Potent BRD4 resor suppresses cancercell-macrophage interaction. Nature Communications.doi:10.1038/s41467-020-15290-0 . Advances in the study of BRD4 inhibitors. Retrieved May 16, 2020, from.